TipRanks
55% OFF
PC:ACC50

Accro Bioscience

Suzhou, Jiangsu, CNhttps://www.accropeutics.com/Therapeutics

A clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulatory cell death for immune-mediated diseases. The company is advancing a multi-asset pipeline including AC-101, a RIPK2 inhibitor in development for ulcerative colitis, aiming to deliver targeted therapies for inflammatory and autoimmune conditions.

Leadership & Board

Latest Estimated Valuation

Estimated Valuation
―
Total Amount Raised
$50M
Total Funding Rounds
1
Latest Funding Amount
$50M
Latest Funding Round
Series C
Post-Money Valuation
―

Funding Round

Funding DateFunding RoundAmount RaisedPost-Money Valuation
May 19, 2026Series C$50.00M―

Investors

Investor NameFunding Round
OrbiMedSeries C
TCG CrossoverSeries C
LAVSeries C
Cenova CapitalSeries C
Shenzhen Capital GroupSeries C
Oriza HoldingsSeries C

Similar Companies

A snapshot of private companies similar to Accro Bioscience, helping you discover and navigate related company profiles.

Related News and Analysis